Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma

Craig Gibbs, PhD, MBA, appointed President and Chief Executive Officer Ellen Lubman, MBA, joins as Chief Business and Strategy Officer Oncology veteran Tim Clackson, PhD, appointed to the Board of Directors FDA grants Safe to Proceed for the Pivotal Phase 3 sTEADfast Clinical Study SAN...